Skip to main content
. 2020 Jun 27;2020:2561726. doi: 10.1155/2020/2561726

Table 2.

Patients' characteristics with the BCSC expression.

BCSC (CD44+ve and CD24−ve) 32 patients Non-BCSC 44 patients P
Premenopausal 22 (68.8%) 21 (47.7%) 0.1
Postmenopausal 10 (31.2%) 23 (52.3%)

Grade II 4 (12.5%) 26 (59.1%) 0.001
Grade III 28 (87.5%) 18 (40.9%)

Luminal A and B 10 (31.2%) 30 (68.2%) 0.006
Her2-amplified 7 (21.9%) 5 (11.4%)
Triple negative 15 (46.9%) 9 (20.4%)

CR, PR, and SD 5 (16.1%) 22 (51.2%) 0.003
Progressed disease 26 (83.9%) 21 (48.8%)